Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 5, 2007, Pages 425-433

  Yoshida, Chikamasa ^a   Niiya, Kenji ^a,b   Niiya, Masami ^a   Shibakura, Misako ^a   Asaumi, Noboru ^a,b   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Kasaoka Hospital   (Japan)

Author keywords

Early growth response 1; Interleukin 8; Mitogen activated protein kinase; Small cell lung cancer; STI571; Urokinase type plasminogen activator

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; IMATINIB; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; U 0124; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE INDUCTION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; EARLY GROWTH RESPONSE PROTEIN 1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MAP KINASE SIGNALING SYSTEM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; URINARY PLASMINOGEN ACTIVATOR;

EID: 34250848217     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32815b6465     Document Type: Article

References (48)

1. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6:3341-3351.
2. Lev S, Blechman JM, Givol D, Yarden Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog 1994; 5:141-168.
3. Pietsch T, Kyas U, Steffens U, Yakisan E, Hadam MR, Ludwig WD, et al. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992; 80:1199-1206.
4. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 1994; 84:3465-3472.
5. Hines SJ, Organ C, Kornstein MJ, Krystal GW. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995; 6:769-779.
6. Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, et al. Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol 1993; 14:295-302.
7. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994; 54:3049-3053.
8. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 1991; 51:1811-1816.
9. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991; 6:2291-2296.
10. Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993; 53:1709-1714.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-566.
12. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145.
13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
14. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042.
15. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
16. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6:3319-3326.
17. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19:3521-3528.
18. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9:5880-5887.
19. Heinrich MC. Is KIT an important therapeutic target in small cell lung cancer? Clin Cancer Res 2003; 9:5825-5828.
20. Kiguchi T, Niiya K, Shibakura M, Miyazono T, Shinagawa K, Ishimaru F, et al. Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells. Int J Cancer 2001; 93:792-797.
21. Shibakura M, Niiya K, Kiguchi T, Kitajima I, Niiya M, Asaumi N, et al. Induction of IL-8 and monoclyte chemoattractant protein-1 by doxorubicin in human small cell lung carcinoma cells. Int J Cancer 2003; 103:380-386.
22. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, et al. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 2003; 52:391-398.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
24. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148:223-234.
25. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
26. Kowalski J, Denhardt DT. Regulation of the mRNA for monocyte-derived neutrophil-activating peptide in differentiating HL60 promyelocytes. Mol Cell Biol 1989; 9:1946-1957.
27. de Grado M, Rosenberger CM, Gauthier A, Vallance BA, Finlay BB. Enteropathogenic Escherichia coli infection induces expression of the early growth response factor by activating mitogen-activated protein kinase cascades in epithelial cells. Infect Immunol 2001; 69:6217-6224.
28. Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K, et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 1987; 47:5616-5619.
29. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80:374-381.
30. Niiya M, Niiya K, Shibakura M, Asaumi N, Yoshida C, Shinagawa K, et al. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells. Oncology 2004; 67:310-319.
31. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003; 2:753-763.
32. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Progr Nucleic Acid Res Mol Biol 1995; 50:191-224.
33. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193:287-292.
34. Khachigian LM, Williams AJ, Collins T. Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J Biol Chem 1995; 270:27679-27686.
35. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 2000; 275:38524-38531.
36. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 1996; 271:1427-1431.
37. Giri RK, Selvaraj SK, Kalra VK. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 2003; 170:5281-5294.
38. Silverman ES, Collins T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999; 154:665-670.
39. Iguchi A, Kitajima I, Yamakuchi M, Ueno S, Aikou T, Kubo T, et al. PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem Biophys Res Commun 2000; 279:166-171.
40. + cells. Blood 2004; 103:3167-3174.
41. Blasi F. The urokinase receptor and cell migration. Semin Thromb Hemost 1996; 22:513-516.
42. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78:285-296.
43. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5:662-668.
44. Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995; 57:752-762.
45. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000; 60:2290-2299.
46. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 2000; 164:2769-2775.
47. Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 2005; 113:849-856.
48. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006; 106:366-374.